Not available
Quote | Trevena Inc. (NASDAQ:TRVN)
Last: | $0.2053 |
---|---|
Change Percent: | -3.48% |
Open: | $0.217 |
Close: | $0.2053 |
High: | $0.2196 |
Low: | $0.2013 |
Volume: | 371,468 |
Last Trade Date Time: | 07/02/2024 03:00:00 am |
News | Trevena Inc. (NASDAQ:TRVN)
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...
Message Board Posts | Trevena Inc. (NASDAQ:TRVN)
Subject | By | Source | When |
---|---|---|---|
Guess I hit that On The Money Whooza | Triple nickle | investorshub | 05/08/2023 5:51:03 PM |
$TRVN: It's QUIET here because the iHub PUNDITS | Invest-in-America | investorshub | 05/08/2023 5:36:44 PM |
Damn! pretty quiet here considering what's going on. | madras50 | investorshub | 05/08/2023 5:15:19 PM |
https://stockcharts.com/h-sc/ui?s=trvn&p=D&yr=0&mn=6&dy=0&id=p38090673899 | surf1944 | investorshub | 05/08/2023 4:34:43 PM |
This is what $LILM is gonna do too ;) | LowFloatLopes | investorshub | 05/08/2023 3:56:07 PM |
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States SMX (Security Matters) Public Limited Company (SMX) rose 43.0% to $0.1702 on volume of 99,421,591 shares NVIDIA Corporation (NVDA) rose 3.5% to $140.3486 on volume of 71,277,917 shares MGO Global Inc. (MGOL) rose 222.9% to $1.48 on vo...
TRV045 shows potential for sustained, long-term analgesic effect in preclinical model of neuropathic pain, with no evidence of receptor desensitization TRV045 demonstrates statistically significant, dose-dependent increase in measures of seizure threshold and shows seizure protection in...
TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 CHESTERBROOK, Pa., May 15, 2024 (GLOBE NEWSWIRE) -- ...